Abbott Named Among the ‘Top Employers’ in the Biotech and Pharmaceutical Sector by Science Magazine Abbott was named among the top 20 companies in Science magazine’s 2010 Top Biopharma Employers survey Click to see more . The annual survey seeks to identify the businesses with the very best reputations as companies. Based on the survey, Abbott’s top three driving characteristics were: clear vision, loyal employees, and does essential, quality research. The complete rankings are available online and in the Oct.
Product sales were reduced by approximately $60 million because of higher Medicaid rebates under U.S. Health care reform. Excluding this effect, sales would have increased 15.5 %. Worldwide pharmaceutical sales elevated 12.9 %, including a good 4.4 % aftereffect of exchange rates, powered by double-digit growth for HUMIRA and Abbott’s lipid management franchise. Worldwide vascular items sales increased 15.8 %, including a favorable 3.2 % aftereffect of exchange rates, driven by strong international growth. Abbott’s XIENCE is currently the number one drug-eluting stent in the world with its successful launch in Japan during the first one fourth. Worldwide nutritional sales elevated 11.8 %, including a favorable 2.6 % effect of exchange rates, driven by strong double-digit growth in international nutritionals.